Disease Landscape and Forecast Insights

The shifting multiple sclerosis (MS) therapy market continues to evolve as new disease-modifying therapies (DMTs) expand treatment choices. Standout Ocrevus (Roche/Genentech) continues to transform…

September 2019Physicians treating renal anemia are limited to iron supplements and erythropoiesis-stimulating agents (ESAs), which, although effective, have significant drawbacks. The hypoxia-…

Diabetic nephropathy (DN), also known as diabetic kidney disease, refers to kidney function damage caused by diabetes. DN is a leading cause of chronic kidney disease (CKD) and is associated with…

Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder characterized by the development and progressive enlargement of fluid-filled cysts in the kidneys. Particularly in the…

The biosimilar/noninnovator sector of the endocrinology market is evolving. Eli Lilly/Boehringer Ingelheim’s Abasaglar/Basaglar was the first biosimilar/noninnovator insulin glargine to launch in…

The treatment of renal cell carcinoma has long been dominated by targeted treatments, including mTOR and angiogenesis inhibitors. However, the introduction of immune checkpoint inhibitors has…

Alopecia areata (AA) is an inflammatory autoimmune skin disease characterized by varying degrees of hair loss. The host immune system targets anagen hair follicles. The primary treatment goal is to…

MARKET OUTLOOK In the past decade, AbbVie’s Humira and Amgen’s Enbrel tumor necrosis factor-alpha (TNF-α) inhibitors and Janssen’s interleukin (IL)-12/23 inhibitor Stelara have been…

MARKET OUTLOOK In the past decade, tumor necrosis factor-alpha (TNF-α) inhibitors, including AbbVie’s Humira and Amgen’s Enbrel, and Janssen’s interleukin IL-12/23 inhibitor Stelara have…

TNF-α inhibitors are well entrenched in the U.S. ulcerative colitis (UC) and Crohn’s disease (CD) markets. Newer biologics that offer alternative treatment options (i.e., Takeda’s Entyvio and…

Treatment of recurrent or metastatic non-nasopharyngeal squamous cell carcinoma of the head and neck (SCCHN) has remained relatively unchanged in the past ten years, and Erbitux-based regimens…

In the past decade, the TNF-α inhibitors Humira (AbbVie) and Enbrel (Amgen) and the IL-12/23 inhibitor Stelara (Janssen) have been leading the U.S. psoriasis biologics market. However, the recent…